In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk ... of how often the drugs were being used off-label for weight loss in the study period, which extended ...
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.
The singer reflected on being ‘so broken and dark’ a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback